c-Met
<p>Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody</p>
... murine c-Met (Figure S1E). Since c-Met antibody used in this study is not cross-reactive to murine c-Met, it would be hard to evaluate toxicity evoked by this bispecific antibody ...
14
c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma
... assay c-MET expression in HCC, and no scoring system can be suggested, c-MET quantification in HCC largely depends on the analytical approach adopted by each individual study, assessing either ...
10
Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells
... the c-Met-specific shRNA-expressing Ad, tumors were further investigated by histological ...of c-Met expression was also observed in the tumor tissues treated with dl/shMet4+5 following 10 ...
15
Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer
... for c-MET in CRC have shown inconsistent ...As MET gene expression is not subject to ligand-dependent negative regulation (Figure 5), our study also indicates that the use of a transcriptional semi- ...
14
Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases
... of c-Met expression in breast cancer specimens as follows: immunohistochemistry (IHC), real-time quantitative PCR (RT-PCR), reverse phase pro- tein lysate microarray (RPPA), fluorescence in situ ...
10
Original Article c-MET expression potentially contributes to the poor prognosis of rhabdomyosarcoma
... that c-MET acted as proto-oncogene in ARMS ...that c-MET functions not only in ARMS, which takes a dominant genetic lesion in an upstream transcription factor, but also in ERMS, wherein the ...
10
Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer
... plasma c-Met levels and the clinicopathological parameters, including age, sex, histological type, EGFR mutation type, and smoking ...plasma c-Met concentration was 601.55 ± 120.94 ng/ml in ...
9
c-Met overexpression in breast cancer with positive axillary lymph node
... between c-Met overexpression and an increased risk of disease ...that c-Met overexpression manifested itself in invasive breast cancer groups with positive lymph nodes in which ...
5
Original Article Expression of MACC1-1 and c-Met in human prostatic cancer and their clinicopathological significance
... and c-Met are overexpression in PCa, and their overexpres- sion correlate to poor prognosis in PCa ...and c-Met may help for the auxiliary diagnosis of bladder cancer and judg- ing the ...
7
<p>Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling</p>
... follows: c-MET (FW 5 ʹ -AAG AGG GCA TTT TGG TTG TG-3 ʹ ; RW 5 ʹ -GAT GAT TCC CTC GGT CAG AA-3 ʹ ), POU5F1 (OCT3/4, FW 5 ʹ -TTC AGC CAA ACG ACC ATC TG-3 ʹ ; RW 5 ʹ -GAA CCA CAC TCG GAC CAC ATC-3 ʹ ), NANOG ...
9
Development of antibody-based c-Met inhibitors for targeted cancer therapy
... or c-Met, a small-molecule inhibitor, cabozantinib (XL184, Exelixis, South San Francisco, CA, USA) became the first agent approved by the FDA for the clinical treatment of progressive metastatic medul- lary ...
10
INC280 inhibits Wnt/β catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c MET amplification
... total c-MET, phosphorylated c-MET, β-catenin, Wnt/β-catenin downstream target gene (c-MYC, CCND1), angiogenic marker (CD31), and EMT marker (SNAIL) were ...
7
c Met–mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma
... a c-Met/ETS-1/matrix metalloproteinase–14 (MMP-14) axis that controls VE-cadherin degradation, Endo-MT, and vascular ...Pharmacological c-Met inhibition induced vessel normalization in patient ...
15
C-met inhibition blocks bone metastasis development induced by renal cancer stem cells
... receptor c-MET, speculating that c-MET targeting could lead to bone metastasis ...expressing c-MET receptor from a primary renal ...a c-MET inhibitor (JNJ-38877605) ...
13
DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C MET and HER3
... and C-MET adds to the current body of literature regarding immunopheno- types of hereditary breast ...and C-MET for both BRCA1 and BRCA2 mutation ...and C-MET oncodriver ...
8
MicroRNA-562 negatively regulated c-MET/AKT pathway in the growth of glioblastoma cells
... and c-MET in GBM, the miR-562 mimic and inhibitor were transfected into two GBM cell lines (U251 and U87), ...of c-MET was upregulated in ...
9
Expression of MACC1 and c-Met in human gastric cancer and its clinical significance
... of c-Met is by action on the Sp1 sites, which is the c-Met startup sequence that enhances the cascade ef- fect of HGF/c-Met signaling pathways ...with c-Met ...
6
Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer
... and c-Met are cell surface proteins that are primarily expressed in epithelial ...and c-Met to be functionally linked in vivo is that they are expressed in close proximity to each other, on ...
12
Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma
... Human hepatocellular carcinoma (HCC) remains a major health problem, as it is the sixth most common cancer and the third most common cause of cancer-related deaths worldwide [1]. There are multiple therapeutic options ...
17
Roles of c-Met and RON Kinases in tumor progression and their potential as therapeutic targets
... a c-Met TKI has gone through phase II trials as a single agent or in combination with other targeted agents or chemotherapy ...of c-Met [73]. High levels of c-Met was defined as ...
12